PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia

International Journal of Gynecological Pathology

Volumn 31, Issue 2, 2012, Pages 159-167

  Allison, Kimberly H ^a   Upson, Kristen ^a   Reed, Susan D ^a,b,c   Jordan, Carolyn D ^a   Newton, Katherine M ^a,c   Doherty, Jennifer ^b   Swisher, Elizabeth M ^a,b   Garcia, Rochelle L ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Endometrial hyperplasia; Endometrial neoplasia; Endometrium; Immunohistochemistry; PAX2

Indexed keywords

TRANSCRIPTION FACTOR PAX2;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84857155080     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318226b376     Document Type: Article

References (31)

1. Beutler HK, Dockerty MB, Randall LM. Precancerous lesions of the endometrium. Am J Obstet Gynecol 1963;86:433-43.
2. Campbell PE, Barter RA. The significance of a typical endometrial hyperplasia. J Obstet Gynaecol Br Commonw 1961;68:668-72.
3. Gore H, Hertig AT. Carcinoma in situ of the endometrium. Am J Obstet Gynecol 1966;94:134-55.
4. Gusberg SB, Kaplan AL. Precursors of corpus cancer. Iv. Adenomatous hyperplasia as stage O carcinoma of the endometrium. Am J Obstet Gynecol 1963;87:662-78.
5. Hendrickson M KR. Surgical Pathology of the Uterine Corpus Vol. Philadelphia: WB Saunders Co 1980.
6. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients. Cancer 1985;56:403-12. (Pubitemid 15031667)
7. Tavassoli F, Kraus FT. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol 1978;70:770-9. (Pubitemid 9071279)
8. Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:804-11. (Pubitemid 43238447)
9. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287-90. (Pubitemid 30131494)
10. Mutter GL, Zaino RJ, Baak JP, et al. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007;26:103-14. (Pubitemid 46573204)
11. Allison KH, Reed SD, Voigt LF, et al. Diagnosing endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008;32:691-8 (Pubitemid 351600820)
12. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999;23:1102-8. (Pubitemid 29409773)
13. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22:1012-9. (Pubitemid 28364502)
14. Skov BG, Broholm H, Engel U, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol 1997;16:33-7. (Pubitemid 27199583)
15. Tavassoli FA DPE, ed. World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003.
16. Horn LC SU, Bilek K, Hentschel B, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestin treatment. Int J Gynecol Cancer 2004;14:348-53. (Pubitemid 38533908)
17. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-9. (Pubitemid 43238448)
18. Lacey JV Jr, Mutter GL, Nucci MR, et al. Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 2008;113:2073-81.
19. Gruss P, Walther C. Pax in development. Cell 1992;69:719-22.
20. Lang D, Powell SK, Plummer RS, et al. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007;73:1-14. (Pubitemid 44868976)
21. Kuschert S, Rowitch DH, Haenig B, et al. Characterization of Pax-2 regulatory sequences that direct transgene expression in the Wolffian duct and its derivatives. Dev Biol 2001;229: 128-40. (Pubitemid 32061719)
22. Lechner MS, Dressler GR. The molecular basis of embryonic kidney development. Mech Dev 1997;62:105-20. (Pubitemid 27215781)
23. Tong GX, Melamed J, Mansukhani M, et al. PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol 2006;19:356-63. (Pubitemid 43276989)
24. Torres M, Gomez-Pardo E, Dressler GR, et al. Pax-2 controls multiple steps of urogenital development. Development 1995; 121:4057-65. (Pubitemid 26007357)
25. Tong GX, Chiriboga L, Hamele-Bena D, et al.Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol 2007;20:856-63 (Pubitemid 47077268)
26. Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005;438:981-7. (Pubitemid 43093965)
27. Monte NM,Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 2010;70:6225-32.
28. Reed SD, Newton KM, Clinton WL, et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009;200:678e1-6.
29. Reed SD VL, Newton KM, Garcia RH, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009;113:655-62.
30. Cao D GA, Vang RS, Kurman RJ, et al. Expression of PAX2 in endometrial hyerplasia and carcinomas: immunohistochemical analysis of 136 cases. Mod Pathol 2008;20(suppl 2):Abstract x869.
31. Mutter GL, Lin MC, Fitzgerald JT, et al. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000;85:2334-8. (Pubitemid 32269265)